WO2004030661A3 - Therapeutic compositions comprising a boron-containing compound - Google Patents

Therapeutic compositions comprising a boron-containing compound Download PDF

Info

Publication number
WO2004030661A3
WO2004030661A3 PCT/GB2003/003870 GB0303870W WO2004030661A3 WO 2004030661 A3 WO2004030661 A3 WO 2004030661A3 GB 0303870 W GB0303870 W GB 0303870W WO 2004030661 A3 WO2004030661 A3 WO 2004030661A3
Authority
WO
WIPO (PCT)
Prior art keywords
boron
containing compound
composition
therapeutic compositions
ionising
Prior art date
Application number
PCT/GB2003/003870
Other languages
French (fr)
Other versions
WO2004030661A2 (en
Inventor
Bipin Patel
Ian Flockhart
Ken Rickwood
Original Assignee
Psimei Pharmaceuticals Plc
Bipin Patel
Ian Flockhart
Ken Rickwood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psimei Pharmaceuticals Plc, Bipin Patel, Ian Flockhart, Ken Rickwood filed Critical Psimei Pharmaceuticals Plc
Priority to AU2003260793A priority Critical patent/AU2003260793A1/en
Publication of WO2004030661A2 publication Critical patent/WO2004030661A2/en
Publication of WO2004030661A3 publication Critical patent/WO2004030661A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a composition comprising a boron-containing compound and a polyhydroxy acid in a solution having a pH of 7.5 to 10.5. This composition provides a boron-containing solution at a therapeutically usable level. There is further provided a composition comprising a stable particulate suspension of a boron-containing compound and a surfactant. The boron-containing composition of the present invention are provided for use in the treatment of cancer specifically in boron neutron capture therapy, radiotherapy, or other ionising or non-ionising photon or atomic or sub-atomic particle therapy.
PCT/GB2003/003870 2002-10-03 2003-09-05 Therapeutic compositions comprising a boron-containing compound WO2004030661A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003260793A AU2003260793A1 (en) 2002-10-03 2003-09-05 Therapeutic compositions comprising a boron-containing compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0222945.8 2002-10-03
GBGB0222945.8A GB0222945D0 (en) 2002-10-03 2002-10-03 Therapeutic compositions

Publications (2)

Publication Number Publication Date
WO2004030661A2 WO2004030661A2 (en) 2004-04-15
WO2004030661A3 true WO2004030661A3 (en) 2004-09-30

Family

ID=9945241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003870 WO2004030661A2 (en) 2002-10-03 2003-09-05 Therapeutic compositions comprising a boron-containing compound

Country Status (3)

Country Link
AU (1) AU2003260793A1 (en)
GB (1) GB0222945D0 (en)
WO (1) WO2004030661A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111117124B (en) * 2018-10-30 2021-02-12 华南理工大学 Hot water soluble polyvinyl alcohol film and preparation method and application thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863484B1 (en) * 2003-12-11 2007-04-13 Oreal USE OF COMPOUNDS CAPABLE OF ACTING ON THE METABOLIC PATHWAY CONTROLLED BY DOPACHROME TAUTOMERASE TRP-2 AS PROTECTIVE AGENT OF MELANOCYTES OF FOLLICLE AND APPLICATIONS
GB0404708D0 (en) * 2004-03-02 2004-04-07 Cellic As T Boron containing nanoparticles
US6995260B2 (en) * 2004-05-20 2006-02-07 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8287839B2 (en) 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
KR102586137B1 (en) 2017-04-07 2023-10-05 노쓰 캐롤라이나 스테이트 유니버시티 Additives for fiber reinforcement
KR102562968B1 (en) * 2018-11-01 2023-08-04 주식회사 셀비온 p-Boronophenylalanine composition for Boron Neutron Capture Therapy and preparing method thereof
EP3960204A4 (en) * 2019-04-26 2022-07-06 Neuboron Medtech Ltd. Bpa lyophilized preparation and preparation method therefor
KR20220062368A (en) * 2019-09-12 2022-05-16 스텔라파머 가부시키가이샤 Method for preventing precipitation of injection solution containing p-boronophenylalanine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693704A1 (en) * 1994-07-22 1996-01-24 Rockwell International Corporation Semi-organic crystals for nonlinear optical devices
WO2000057887A1 (en) * 1999-03-31 2000-10-05 Glycosyn Pharmaceuticals, Inc. p-BORONOPHENYLALANINE COMPLEXES WITH FRUCTOSE AND RELATED CARBOHYDRATES AND POLYOLS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693704A1 (en) * 1994-07-22 1996-01-24 Rockwell International Corporation Semi-organic crystals for nonlinear optical devices
WO2000057887A1 (en) * 1999-03-31 2000-10-05 Glycosyn Pharmaceuticals, Inc. p-BORONOPHENYLALANINE COMPLEXES WITH FRUCTOSE AND RELATED CARBOHYDRATES AND POLYOLS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBAYASHI M ET AL: "COMPLEX FORMATION OF BORIC ACIDS WITH DI- AND TRI- CARBOXYLIC ACIDSAND POLY(VINYL ALCOHOL) IN AQUEOUS SOLUTIONS", MACROMOLECULAR SYMPOSIA, WILEY VCH, WEINHEIM, DE, vol. 114, 1 February 1997 (1997-02-01), pages 303 - 308, XP000700556, ISSN: 1022-1360 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111117124B (en) * 2018-10-30 2021-02-12 华南理工大学 Hot water soluble polyvinyl alcohol film and preparation method and application thereof

Also Published As

Publication number Publication date
WO2004030661A2 (en) 2004-04-15
AU2003260793A8 (en) 2004-04-23
AU2003260793A1 (en) 2004-04-23
GB0222945D0 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
Dale Dose-rate effects in targeted radiotherapy
NZ513960A (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2004030661A3 (en) Therapeutic compositions comprising a boron-containing compound
WO2005061009A3 (en) Microparticles for microarterial imaging and radiotherapy
RS20050802A (en) Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis
EP0972517A3 (en) Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours
MXPA03005394A (en) Compositions containing inclusion complexes.
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
Dahle et al. Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy
HK1107283A1 (en) Method and device for radiotherapy
WO2004014320A3 (en) Methods of using beta glucan as a radioprotective agent
CA2534816A1 (en) Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
ATE198046T1 (en) NEW INHIBITORS OF URIDINE PHOSPHORYLASE (URDPASE) AND DIHYDROURACILDEHYDROGENASE (DHUDASE)
EP1178988A4 (en) Compounds and therapeutic methods
JP7068222B2 (en) High-purity therapeutic bone agent
UA81634C2 (en) Pharmaceutical compoosition containing urease for inhibiting cancer cell growth
CA2483826A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
Kassis et al. Therapeutic potential of 5‐[125I] iodo‐2′‐deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis
JP2015510496A5 (en)
AU2003241024A1 (en) Methods and compositions for radioimmunotherapy of brain and cns tumors
MXPA05010804A (en) Thorium-227 for use in radiotherapy of soft tissue disease.
Guilmette et al. Interaction of Pu and Am with bone mineral in vitro
IL165323A0 (en) Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP